

2019年度 業績

「英文論文」

1. [Kuroiwa K, Inokuchi J, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yokomizo A, Matsuyama H, Ichikawa T, Mizusawa J, Eba J, Naito S; JCOG UOSG. Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. J Urol. 2019 Dec;202\(6\):1127-1135. doi: 10.1097/JU.0000000000000422. . doi: 10.1097/JU.0000000000000422. \[Epub ahead of print\]](#)
2. [Shiraishi K, Kitahara S, Ito H, Oba K, Ohmi C, Matsuyama H. Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for large pheochromocytoma: Comparative outcomes. Int J Urol. 2019 Feb;26\(2\):212-216. doi: 10.1111/iju.13838.](#)
3. [Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. Cancer Sci. 2019 Jun;110\(6\):1820-1828. doi: 10.1111/cas.14019](#)
4. [Sakamoto S, Maimaiti M, Xu M, Kamada S, Yamada Y, Kitoh H, Matsumoto H, Takeuchi N, Higuchi K, Uchida HA, Komiya A, Nagata M, Nakatsu H, Matsuyama H, Akakura K, Ichikawa T. Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. J Clin Med. 2019 Apr 11;8\(4\). pii: E489. doi: 10.3390/jcm8040489.](#)
5. [Shiraishi K, Matsuyama H. Klinefelter syndrome: From pediatrics to geriatrics. Reprod Med Biol. 2018 Dec 8;18\(2\):140-150. doi: 10.1002/rmb2.12261](#)
6. [Shiraishi K, Tabara M, Matsuyama H. High Inguinal Microsurgical Denervation of the Spermatic Cord for Chronic Scrotal Content Pain: A Novel Approach for Adult and Pediatric Patients. Urology. 2019 Sep;131:144-149. doi: 10.1016/j.urology.2019.05.013](#)
7. [Suzuki K, Matsubara N, Kazama H, Seto T, Tsukube S, Matsuyama H. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Jpn J Clin Oncol . 2019 Dec 27;49\(12\):1157-1163. doi: 10.1093/jjco/hyz108.](#)
8. [Yamamoto Y, Otori T, Inoue R, Yano S, Hirata H, Matsumoto H, Matsuyama K, Matsuyama H. Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in](#)

- Patients With Advanced Renal Cell Carcinoma. J Clin Pharmacol. 2020 Feb;60(2):256-263. doi: 10.1002/jcph.1521.
9. Matsuyama H. IJU this issue. Int J Urol. 2019 Dec;26(12):1089. doi: 10.1111/iju.14155.
 10. Yamamoto Y, Matsuyama H, Matsumoto H, Sakano S, Fuji N, Oba K, Yamamoto M, Kamiryo Y, Hiragino T, Nagao K, Takai K, Aoki A. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J Clin Oncol. 2020 Feb 17;50(2):214-220. doi: 10.1093/jjco/hyz168.
 11. Shiraishi K, Tabara M, Matsuyama H. Transcriptome Analysis to Identify Human Spermatogonial Cells from Sertoli Cell Only Testes. J Urol. 2020 Apr;203(4):809-816. doi: 10.1097/JU.0000000000000682.
 12. Matsumoto H. Editorial Comment from Dr Matsumoto to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. Int J Urol. 2019 Nov;26(11):1069-1070.
 12. Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S, Yokoyama M, Enokida H, Takahashi K, Tanaka Y, Imai K, Shimamoto T, Perini R, Frenkl T, Bajorin D, Bellmunt J. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol. 2020 Jan;25(1):165-174. doi: 10.1007/s10147-019-01545-4.

「和文論文」

1. 白石晃司、松山豪泰. 精索静脈瘤：酸化ストレスと sperm DNA fragment (総説). 西日泌尿. 2019; 81 : 197-207.
2. 松本洋明、佐本征弘、井上 亮、磯山直仁、白石晃司、松山豪泰. PARP 術後尿失禁におけるサルコペニア関連因子及び膜様部尿道長との関連. Jpn. J. Endourol. 2019; 32: 236-240.
3. 長光涼子、松村正文、田原正則、中山祐起、磯山直仁、藤川公樹、松山豪泰. 単腎の腎動脈狭窄に対し自家腎移植を施行した女兒の 1 例. 西日本泌尿. 2019; 81: 522-525.
4. 松本洋明、白石晃司、松山豪泰. 【診療ガイドラインの読み方ガイダンス】新しい手引きに従ったガイドライン作成手順 文献検索まで(解説/特集). 泌尿器外科 (0914-6180)32 巻 7 号 Page913-920(2019.07)
5. 松本洋明、松山豪泰. 【ハイリスク前立腺癌を深掘りする-その変遷と M0 CRPC の最新治療】局所ハイリスク前立腺癌における課題 全摘除術後のアジュバントまたはサルベージ治療(解説/特集). 臨床泌尿器科 (0385-2393)73 巻 8 号 Page526-529(2019.07)
6. 松本洋明、松山豪泰、佐本征弘、森 純一、清水宏輔、井上 亮、山本義明、矢野誠司、長尾一公、平田 寛、島袋智之. 上部尿路上皮癌における炎症・免疫環境因子によるリスク分類の構築. (第 70 回西日本泌尿器科学会総会 学術奨励賞) 西日泌尿. 2019; 81:571-577.
7. 山本義明、井上亮、松村正文、矢野誠司、松本洋明、松山豪泰産. 学連携による DNA microarray を用いた抗 PD-1 抗体治療効果予測のための MSI 癌の探索的研究. 西日本泌尿器科 81(3): 348-352, 2019.